For years the world’s biggest drugmakers paid up for deals. Now they are writing much smaller checks. After shelling out tens of billions of dollars for single biotech companies, pharmaceutical giants such as AbbVie, AstraZeneca and Merck & Co. have shifted to smaller targets costing $5 billion or less. Many of the companies getting taken out are private. The reason, according to executives, bankers and lawyers: Smaller deals are just easier to do in the current regulatory environment, and the sector is looking pretty picked over.
Read the full article: Big Drugmakers Are Clinching Smaller Deals //
Source: https://www.wsj.com/health/pharma/big-drugmakers-are-clinching-smaller-deals-0c039593